Molecular determinants of resistance to CDK4/6 inhibition in ER plus breast cancer

被引：0
|
作者：
Luo, F. [1 ,2 ]
Cowley, G. [3 ]
Garraway, L. [1 ,2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Broad Inst, Med Oncol, Boston, MA USA
[3] Janssen Pharmaceut Co, Johnson & Johnson, Funct Genom, Discovery Sci, Perkasie, PA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32819-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
224
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [31] Longitudinal, multimodal profiling of metastatic ER plus breast cancer on CDK4/6 inhibitor therapy
    Creason, Allison L.
    Egger, Julian
    Watson, Cameron
    Sivagnanam, Shamilene
    Lin, Jia-Ren
    Chin, Koei
    Sorger, Peter K.
    Coussens, Lisa M.
    Mitri, Zahi I.
    Gray, Joe W.
    Mills, Gordon B.
    Goecks, Jeremy
    CANCER RESEARCH, 2023, 83 (07)
  • [32] Acquired sensitivity strategies in ER plus breast cancer progressing on CDK4/6 and mTOR inhibitors
    Farmaki, Eleni
    Emond, Rena
    Cosgrove, Patrick
    Bild, Andrea
    CANCER RESEARCH, 2022, 82 (04)
  • [33] Resistance mechanisms to CDK4/6 Inhibition
    O'Leary, Ben
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 589 - 589
  • [34] LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER plus breast cancer
    Jin, Xi
    Ge, Li-Ping
    Li, Qiang
    Zhao, Naiqing
    Di, Gen-Hong
    Xu, Xiao-En
    Jiang, Yizhou
    MOLECULAR CANCER, 2020, 19 (01)
  • [35] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER GENE THERAPY, 2022, 29 (06) : 859 - 869
  • [36] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Olesya A. Kharenko
    Reena G. Patel
    Cyrus Calosing
    Edward H. van der Horst
    Cancer Gene Therapy, 2022, 29 : 859 - 869
  • [37] CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER
    不详
    CANCER DISCOVERY, 2015, 5 (02) : 107 - 107
  • [38] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
    Luigi Formisano
    Yao Lu
    Alberto Servetto
    Ariella B. Hanker
    Valerie M. Jansen
    Joshua A. Bauer
    Dhivya R. Sudhan
    Angel L. Guerrero-Zotano
    Sarah Croessmann
    Yan Guo
    Paula Gonzalez Ericsson
    Kyung-min Lee
    Mellissa J. Nixon
    Luis J. Schwarz
    Melinda E. Sanders
    Teresa C. Dugger
    Marcelo Rocha Cruz
    Amir Behdad
    Massimo Cristofanilli
    Aditya Bardia
    Joyce O’Shaughnessy
    Rebecca J. Nagy
    Richard B. Lanman
    Nadia Solovieff
    Wei He
    Michelle Miller
    Fei Su
    Yu Shyr
    Ingrid A. Mayer
    Justin M. Balko
    Carlos L. Arteaga
    Nature Communications, 10
  • [39] CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Li, Qing
    Razavi, Pedram
    Li, Zhiqiang
    Paula, Arnaud F. Da Cruz
    Brogi, Edi
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2019, 79 (13)
  • [40] CDK4/6 inhibition in early and metastatic breast cancer: A review
    de Groot, A. F.
    Kuijpers, C. J.
    Kroep, J. R.
    CANCER TREATMENT REVIEWS, 2017, 60 : 130 - 138
12345